Shandong Sito Bio-technology Co., Ltd.

300583

CNE100002F36

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
15.59 ^CNY	-6.65%		+5.98%	-21.18%

May. 08	Shandong Sito Bio-technology Gets European Suitability Certification for Rhinitis Nasal Spray	MT
Apr. 28	Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shandong Sito Bio-Technology Co., Ltd. Appoints Kang Li as Independent Director

December 10, 2023

Shandong Sito Bio-technology Co., Ltd. announced that at the Extraordinary General Meeting of 2023 held on 08 December 2023 elected Kang Li as independent director.

Latest news about Shandong Sito Bio-technology Co., Ltd.

Shandong Sito Bio-technology Gets European Suitability Certification for Rhinitis Nasal Spray	May. 08	MT
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 28	CI
Shandong Sito Bio-Technology Co., Ltd. Appoints Kang Li as Independent Director	Dec. 10	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-20	CI
Shandong Sito Bio-technology in Talks to Buy 60% of Local Steroid Maker for 46 Million Yuan	23-10-16	MT
Shandong Sito Bio-technology Co., Ltd. agreed to acquire 60% stake in Yingu Pharmaceutical Co., Ltd. from Yingu Holding Group for approximately CNY 460 million.	23-10-15	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-30	CI
Shandong Sito Bio-Technology Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 28 June 2023	23-05-17	CI
Shandong Sito Bio-technology Co., Ltd. Proposes Final Cash Dividend for 2022	23-04-25	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-18	CI
Shandong Sito Bio-technology Co., Ltd. announced that it has received CNY 261.590392 million in funding from a group of investors	23-04-06	CI
Sito Bio-technology Selling 300 Million Yuan Shares to Fund New Factory	23-03-13	MT
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-19	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Shandong Sito Bio-Technology Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022	22-06-28	CI
Shandong Sito Bio-technology Co., Ltd. announced that it expects to receive CNY 298.0822 million in funding from a group of investors	22-05-24	CI
Shandong Sito Bio-technology Co., Ltd. Approves Cash Dividend for the Year 2021	22-05-23	CI
Shandong Sito Bio-Technology Co., Ltd. Proposes Final Dividend for 2021	22-04-26	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Shandong Sito Bio-technology Co., Ltd. cancelled the transaction announced on July 16, 2021	22-04-04	CI
Junlanghui Enterprise Management Partnership (Limited Partnership) signed a share transfer agreement to acquire a 5% stake in Shandong Sito Bio-technology Co., Ltd. (SZSE : 300583) from Shandong Runxin Investment Co., Ltd. for approximately CNY 140 million.	22-03-07	CI
Chinese cities ease home purchase down-payments to reignite demand	22-02-18	RE
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Shandong Sito Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI

Chart Shandong Sito Bio-technology Co., Ltd.

Duration

Period

Chart Shandong Sito Bio-technology Co., Ltd.

More charts

Shandong Sito Bio-technology Co Ltd is a company that provides raw materials for pharmaceutical companies. The Company operates three product segments. The Steroid Raw Materials segment is engaged in the manufacturing of steroid raw materials using genetic engineering technology and microbial transformation technology, such as androstenedione, androstenedione, 9-hydroxyandrostenedione, hydroxyprogesterone and so on. The Company also operates Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment through its subsidiary.

Sector

Pharmaceuticals

Calendar

2024-06-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.59

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANDONG SITO BIO-TECHNOLOGY CO., LTD.	-21.18%	409M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals